Literature DB >> 9696351

Involvement of a Gardos-type potassium channel in head activator-induced mitosis of BON cells.

S T Kayser1, H Ulrich, H C Schaller.   

Abstract

The human neuroendocrine cell line BON was used to study second messengers involved in signal transduction for entry into mitosis. BON cells produce the neuropeptide head activator (HA) and use it as autocrine growth factor. HA stimulates BON cell proliferation by triggering entry into mitosis. HA-induced mitosis is mediated by an inhibitory G protein, the action of which is blocked by pertussis toxin. HA signaling requires inhibition of the cAMP pathway, calcium influx, and hyperpolarization of cells. The latter is a very important and sensitive step involving a calcium-activated potassium channel. Cell cycle progression and proliferation of BON cells are most efficiently inhibited with specific inhibitors of this potassium channel. Pharmacology and RNA analysis suggest identity with the recently cloned Gardos-type potassium channel.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696351     DOI: 10.1016/s0171-9335(98)80024-1

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  3 in total

Review 1.  [Regenerative medicine. New therapeutic methods in otorhinolaryngology and head and neck surgery].

Authors:  H Löwenheim
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

2.  Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development.

Authors:  Atanas Ignatov; Julia Lintzel; Irm Hermans-Borgmeyer; Hans-Jürgen Kreienkamp; Patrick Joost; Susanne Thomsen; Axel Methner; H Chica Schaller
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 3.  Role of voltage-gated potassium channels in cancer.

Authors:  L A Pardo; C Contreras-Jurado; M Zientkowska; F Alves; W Stühmer
Journal:  J Membr Biol       Date:  2005-06       Impact factor: 2.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.